Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22958 | 0.97 | CYP2C19 (0.38) | FFAR3CYP2C19AKR1C1ALDH1A1TSHR | |
| SCHEMBL1091337 | 0.95 | FFAR3 (0.38) | FFAR3CYP2C19ALDH1A1TSHR | |
| SCHEMBL1091552 | 0.89 | FFAR3 (0.41) | FFAR3ALDH1A1TSHR | |
| SCHEMBL2761157 | 0.81 | — | — | |
| SCHEMBL13446470 | 0.80 | FFAR3 (0.40) | FFAR3ALDH1A1 | |
| SCHEMBL11379072 | 0.80 | CYP2C19 (0.37) | FFAR3CYP2C19AKR1C1ALDH1A1TSHR | |
| SCHEMBL11373556 | 0.80 | CYP2C19 (0.37) | FFAR3CYP2C19AKR1C1ALDH1A1TSHR | |
| SCHEMBL13446442 | 0.80 | CYP1A2 (0.40) | CYP2C19ALDH1A1 | |
| SCHEMBL15925089 | 0.79 | — | — | |
| SCHEMBL13223471 | 0.79 | GAA (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-11-02 | — | — | US | disclosed |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2021-07-15 | — | — | US | disclosed |
| US-9938236-B2 | Antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| US-9018383-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-04-28 | — | — | US | disclosed |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-03-27 | — | — | US | disclosed |
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, EIF2AK2, NR1H4 | FFAR3 1950/4885CYP2C19 1094/4885AKR1C1 762/4885 |
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | FFAR3 54/4885CYP2C19 2273/4885AKR1C1 912/4885 |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | MGLL, LIPA, PNLIP | FFAR3 1484/4885CYP2C19 4567/4885AKR1C1 3100/4885 |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | OPRL1, MGLL, VKORC1L1 | FFAR3 2931/4885CYP2C19 958/4885AKR1C1 145/4885 |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | FFAR3 54/4885CYP2C19 2273/4885AKR1C1 912/4885 |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | OPRL1, MGLL, OPRK1 | FFAR3 2412/4885CYP2C19 2117/4885AKR1C1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.